Linear, an enterprise software maker that competes with many of Atlassian's products, announced that it raised $82 million in a Series C funding round led by Accel.

Salt Lake City, May 06, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning ...

Recursion Pharmaceuticals stock isn't a good fit for risk-averse investors. The company remains unprofitable and is losing more money as it ramps up clinical development of several candidates.

Watching linear TV may seem very 2010, but a surprising number of US consumers still tune in to non-streaming TV services – and they are second screen online shopping while they do so. So, does linear ...

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection ...

Get NCERT solutions for Class 10 maths Chapter 3 Pair of Linear Equations in Two Variables to find the right approach for solving all NCERT questions. Download PDF here!

Recursion’s SYCAMORE Study Meets Primary Goal but Efficacy Lags Recursion reported that its phase II SYCAMORE study met the primary endpoint of safety and tolerability in CCM patients treated ...

Recursion presents mixed data on lead AI-derived drug candidate for potentially fatal brain condition While a success on paper, the Phase 2 results likely won’t satisfy many investors ...

--Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the completion of BioHive-2, Recursion’ s new NVIDIA DGX SuperPOD AI ...